You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Baseline characteristics of patientsa

From: Differences in the quality of oral anticoagulation therapy with vitamin K antagonists in German GP practices – results of the cluster-randomized PICANT trial (Primary Care Management for Optimized Antithrombotic Treatment)

  Intervention (n = 365) Control (n = 371) Total (n = 736)
Sociodemographic characteristics  
Age, mean (SD), yearsb 74.4 (9.5) 72.8 (9.3) 73.6 (9.4)
Male gender, no. (%) 205 (56.2) 200 (53.9) 405 (55.0)
Educational attainment, no. (%)
 No educational attainment 54 (15.9%) 38 (11.3%) 92 (13.6%)
 Vocational training 2 (0.6%) 0 (0%) 2 (0.3%)
 Vocational on-the-job training 145 (42.8%) 153 (45.4%) 298 (44.1%)
 On-the-job training combined with school-based education 38 (11.2%) 46 (13.6%) 84 (12.4%)
 Education in a technical college 56 (16.5%) 47 (13.9%) 103 (15.2%)
 Polytechnic degree 25 (7.4%) 25 (7.4%) 50 (7.4%)
 University degree 19 (5.6%) 28 (8.3%) 47 (7%)
BMI, mean (SD) 28.8 (5.1) 29.1 (4.8) 28.9 (5.0)
Smoking, no. (%)
 Non-smoker 185 (51.5%) 205 (56%) 390 (53.8%)
 Former smoker 151 (42.1%) 136 (37.2%) 287 (39.6%)
 Occasional smoker 9 (2.5%) 11 (3%) 20 (2.8%)
 Regular smoker 14 (3.9%) 14 (3.8%) 28 (3.9%)
Migration background, no. (%) 27 (7.4) 24 (6.5) 51 (6.9)
Clinical characteristics
Long-term indication for oral anticoagulation therapy, no. (%)c
  Atrial fibrillation/flutter 302 (82.7) 295 (79.5) 597 (81.1)
  Recurrent venous thromboembolism 32 (8.8) 40 (10.8) 72 (9.8)
  Recurrent pulmonary embolism 31 (8.5) 30 (8.1) 61 (8.3)
  Mechanical heart prosthesis 29 (7.9) 28 (7.5) 57 (7.7)
  Intracardiac thrombus 3 (0.8) 4 (1.1) 7 (1.0)
  Other indication 33 (9.0) 34 (9.2) 67 (9.1)
Comorbidities, no. (%)c
 Ischemic heart disease 133 (36.4%) 106 (28.6%) 239 (32.5%)
 Cerebral insult/bleeding 72 (19.7%) 56 (15.1%) 128 (17.4%)
 Congestive heart failure 120 (32.9%) 103 (27.8%) 223 (30.3%)
 Peripheral arterial occlusive disease (PAOD) 39 (10.7%) 26 (7%) 65 (8.8%)
 Arterial hypertension 317 (86.8%) 307 (82.7%) 624 (84.8%)
 Renal insufficiency 62 (17%) 63 (17%) 125 (17%)
 Diabetes mellitus 119 (32.6%) 135 (36.4%) 254 (34.5%)
 Chronic pulmonary diseases 58 (15.9%) 63 (17%) 121 (16.4%)
 Diseases of the esophagus, stomach, duodenum 68 (18.6%) 63 (17%) 131 (17.8%)
 Malignant tumor 18 (4.9%) 23 (6.2%) 41 (5.6%)
CHA2DS2-VASc-Score, no. (%)d
  > 1 292 (97.0) 282 (95.9) 574 (96.5)
  = 1 9 (3.0) 12 (4.1) 21 (3.5)
Antithrombotic medication, no. (%)e
 Phenprocoumon 341 (93.4) 349 (94.1) 690 (93.8)
 Dabigatran 8 (2.2) 4 (1.1) 12 (1.6)
 Rivaroxaban 7 (1.9) 13 (3.5)) 20 (2.7)
 Aspirin 4 (1.1) 6 (1.6) 10 (1.4)
 Other 9 (2.5) 3 (0.8) 12 (1.6)
Last INR within therapeutic target range, no. (%)f 240 (69.2) 239 (68.7) 479 (68.9)
INR self-measurement, no. (%)g 39 (11.3) 46 (13.3) 85 (12.3)
Patient compliance, no. (%)h
 Highly compliant 308 (84.4) 266 (72.1) 574 (78.2)
 Moderately compliant 51 (14.0) 86 (23.3) 137 (18.7)
 Not compliant 6 (1.6) 17 (4.6) 23 (3.1)
  1. aThis is a slightly different version of the original table from the main study [24]
  2. bAge was calculated from 15/mm/yyyy since the exact birth date was not documented to ensure data privacy
  3. cPatients may have had more than one indication, and/or more than one comorbidity
  4. dRefers to 595 patients with atrial fibrillation/flutter and available data
  5. eApixaban and Edoxaban had not been approved at the time of the baseline assessment
  6. fOnly considers patients receiving phenprocoumon; target INR range as defined by GP
  7. gDistinction between self-measurement yes and no, dose adjustment not taken into account
  8. hCompliance was assessed for each patient by his GP; data available for 369 patients in control group